
    
      This is a multi-national, multi-center, open-label, single-arm study. All subjects will be
      males with prostate cancer judged to be candidates for medical androgen ablation therapy and
      all will receive two injections of LMIS 25 mg twelve-week apart in an unblinded fashion.
    
  